Research programme: cancer therapeutics - Lakefront Biotherapeutics/Servier
Latest Information Update: 10 May 2026
At a glance
- Originator Galapagos NV; Servier
- Developer Lakefront Biotherapeutics; Servier
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer